Latest From PharmaMar SA
Lilly licenses non-opioid pain candidate from Centrexion. China’s Hansoh gets rights to inibelizumab from AstraZeneca spinout Viela for lead indication neuromyelitis optica as well as other autoimmune and blood cancer indications.
The Japanese pharma, continuing to bolster its pipeline after buying Shire, is partnering with Skyhawk in neurodegenerative diseases under another new deal. Also, Purdue cites shifting business priorities for a decision to end Eisai collaboration on sleep disorder drug.
Start-ups in Spain will descend on the Andalusian city next week for the BioSpain meeting in search of national and international investors and collaborators to boost their respective R&D pipelines.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- PharmaMar SA
- Senior Management
José María Fernández Sousa-Faro, PhD, Pres. & CEO
Maria Luisa de Francia Caballero, CFO
- Contact Info
Phone: (34) 91 846 6000
Avda. De los Reyes,1 Pol. Ind.
Colmenar Viejo, Madrid, 28770
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.